ExodusPoint Capital Management LP Takes Position in Twist Bioscience Co. (NASDAQ:TWST)

ExodusPoint Capital Management LP purchased a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 39,300 shares of the company's stock, valued at approximately $1,826,000. ExodusPoint Capital Management LP owned approximately 0.07% of Twist Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently made changes to their positions in TWST. Thrivent Financial for Lutherans increased its holdings in Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after purchasing an additional 532,040 shares in the last quarter. State Street Corp grew its holdings in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock worth $143,101,000 after buying an additional 526,028 shares in the last quarter. Wellington Management Group LLP raised its position in Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock valued at $36,042,000 after buying an additional 521,272 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Twist Bioscience by 80.2% in the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock valued at $31,636,000 after purchasing an additional 302,884 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Twist Bioscience by 63.5% during the fourth quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock worth $35,148,000 after acquiring an additional 293,751 shares in the last quarter.

Remove Ads

Twist Bioscience Trading Down 0.1 %

NASDAQ TWST traded down $0.04 during trading hours on Monday, reaching $38.81. The company's stock had a trading volume of 156,716 shares, compared to its average volume of 975,426. The firm has a fifty day simple moving average of $41.83 and a 200-day simple moving average of $44.65. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The stock has a market cap of $2.32 billion, a P/E ratio of -11.48 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the business posted ($0.75) earnings per share. Twist Bioscience's quarterly revenue was up 24.1% on a year-over-year basis. Equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the topic of a number of research analyst reports. Barclays dropped their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research report on Friday, March 28th. Finally, JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $52.80.

Insider Transactions at Twist Bioscience

In related news, SVP Paula Green sold 1,259 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65. Following the completion of the sale, the senior vice president now owns 132,014 shares in the company, valued at approximately $6,514,890.90. This represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Dennis Cho sold 806 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the transaction, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,796 shares of company stock valued at $1,077,383. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.